Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial - Summary - MDSpire

Efficacy and Safety of Deucravacitinib in Patients with Active Psoriatic Arthritis: Results from the Phase 3 POETYK PsA-2 Trial Over 52 Weeks

  • By

  • Philip J. Mease

  • Vinod Chandran

  • April W. Armstrong

  • Ricardo Blanco

  • Alexis Ogdie

  • Evan L. Siegel

  • Alice B. Gottlieb

  • Xiaofeng Zeng

  • Diamant Thaçi

  • Mitsumasa Kishimoto

  • Hendrik Schulze-Koops

  • Alan Kivitz

  • Eva Dokoupilová

  • Akimichi Morita

  • Eric M. Ruderman

  • Michael Plewinski

  • Kejia Wang

  • Caroline Sardinas

  • Eleni Vritzali

  • John Vaile

  • Atul Deodhar

  • July 20, 2026

Share

Objective:

To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease-modifying antirheumatic drugs or received tumor necrosis factor inhibitors.

Approach:
  • Study Design: The 52-week, double-blind, placebo-controlled, phase 3 POETYK PsA-2 study (NCT04908189) randomized patients 3:3:1 to deucravacitinib 6 mg daily, placebo, or apremilast 30 mg twice daily (safety reference arm) through Week 16.
  • Treatment Continuation: From Week 16 to Week 52, patients continued receiving deucravacitinib or apremilast or switched from placebo to deucravacitinib.
  • Primary Endpoint: The primary endpoint was American College of Rheumatology 20% improvement in response (ACR20).
Key Findings:
  • Deucravacitinib demonstrated significant efficacy in achieving ACR20 response compared to placebo.
  • Safety profile of deucravacitinib was consistent with previous studies.
Interpretation:

Limitations:
  • The study population may not represent all patients with psoriatic arthritis.
  • Long-term safety and efficacy beyond 52 weeks remain to be established.
Conclusion:

Sources:

Original Source(s)

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial

  • by Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze-Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar

  • July 20, 2026

Related Content

Comparative treatment persistence of upadacitinib vs. tofacitinib in psoriatic arthritis: a multicenter observational study from the BIRRA cohort

​​​​​​​PsA Treatment Options Expand

Phase 3 POETYK trial results support FDA approval of deucravacitinib for adults with active PsA.

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.